TY - JOUR T1 - Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2021-220771 SP - annrheumdis-2021-220771 AU - Timothée Klopfenstein AU - Vincent Gendrin AU - Thierry Conrozier AU - Aurélie Gerazime AU - Marc Puyraveau AU - Souheil Zayet Y1 - 2021/06/22 UR - http://ard.bmj.com/content/early/2021/06/23/annrheumdis-2021-220771.abstract N2 - We have read with great interest the study conducted by Ramiro et al1 entitled ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’. This study was among the first publications showing benefit of tocilizumab administration in patients with severe COVID-19-associated cytokine storm syndrome, in July 2020.1 In the same way, we observed a benefit of tocilizumab administration in a cohort of 206 patients during the first wave of the pandemic, in June 2020.2We have now more ‘evidence-based medicine’ to discuss tocilizumab’s place in COVID-19. Thus, nine randomised clinical trials (RCTs)3–11 have been published about tocilizumab administration in COVID-19; however, the effects on mortality remain heterogeneous in these trials.12 We recently made a … ER -